Company profile: Phenomenex
1.1 - Company Overview
Company description
- Provider of consumables and analytical chemistry solutions for separation and purification, serving researchers in industrial, clinical research, governmental and academic labs. Offers LC/HPLC columns (Biozen, Kinetex Core-Shell, Luna), GC columns (Zebron), SPE products (Strata-X PRO), and chromatography connectors (SecurityLINK ET) for drug discovery, pharmaceutical development, food safety, and environmental analysis.
Products and services
- Kinetex Core-Shell LC Columns: Core-shell LC columns engineered to enhance chromatographic performance for various analytical applications in liquid chromatography
- Luna HPLC Columns: Thermally modified fully porous particle HPLC columns that deliver reproducible and scalable separations in high-performance liquid chromatography
- Biozen LC Columns: Biologics-focused LC columns engineered for the analysis of biologics, providing reproducible and scalable separations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phenomenex
InSphero
HQ: Switzerland
Website
- Description: Provider of organotypic biological in vitro 3D microtissues and microtissue-based assays for biochemical compound screening and predictive drug testing, offering human prostate and mammary carcinoma and rat liver microtissues, plus services including compound toxicity testing, cell-invasion assays, and stem-cell research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InSphero company profile →
Bio Products Laboratory
HQ: United States
Website
- Description: Provider of plasma collection and plasma-derived medicines, headquartered in the UK and delivering life-saving treatments worldwide for immune deficiencies, bleeding disorders, infectious diseases, and critical care. Operates 29 US donor centers and supplies human albumin (approved for the Chinese market), plus immunology, critical care, and coagulation disorder products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bio Products Laboratory company profile →
Hemanext
HQ: United States
Website
- Description: Provider of blood processing, storage, and transfusion solutions. Offers Hemanext ONE, a blood container set for processing and storing red blood cells under reduced oxygen and carbon dioxide conditions to improve quality and extend shelf-life.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hemanext company profile →
ADC Bio
HQ: United Kingdom
Website
- Description: Provider of process technology for antibody drug conjugates (ADCs), helping drug developers address conjugation challenges in testing and production of ADC-based anti-cancer drugs, enabling faster, simpler and lower-cost development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADC Bio company profile →
Seraxis
HQ: United States
Website
- Description: Provider of cell replacement therapy and lab-grown pancreatic islets for insulin-dependent diabetes. Offerings include SR-01, which combines lab-grown human islets with a technology to implant these islets without immune suppression; SR1423, a stem cell line maturing into insulin-secreting islets; and lab-grown islets that mimic native pancreatic function and respond to glucose.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seraxis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phenomenex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phenomenex
2.2 - Growth funds investing in similar companies to Phenomenex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phenomenex
4.2 - Public trading comparable groups for Phenomenex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →